Loading company
Kairos Pharma, LTD.
KAPA · NYSE · ·
$1.68-1.2%Sep 29 close
- 1M
- +1.2%
- 6M
- -56.4%
- 1Y
- -79.5%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
What this company sells, and where it sells it, as the filings break it down.
Year to Dec 31, 2025 · $55M
These lines are the breakdown as filed. We could not reconcile them against the total revenue for the same period.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
-$5.82MQ2 2026+0.4%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.
-$5.81MQ2 2026+0.6%
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
-$0.28Q2 2026+6.7%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
20.87MQ2 2026+5.3%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
Everything above comes from Kairos Pharma, LTD.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Share-count jumps we cannot explain: 1.62x around Dec 31, 2025. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (current), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Investing Cash Flow, Dividends paid, Stock-Based Compensation, Depreciation, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
KAPA · NYSE · ·
$1.68-1.2%Sep 29 close